NeoGenomics, Inc. Aktie News

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.

NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO's clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO a...

NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced preliminary fourth quarter and full-year 2025 revenue and also announced a transition of the Company's Chief Financial Officer.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of John P. “Jack” Kenny to its Board of Directors.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced that Natera has voluntarily withdrawn its appeal in ongoing RaDaR patent litigation.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will present data on its RaDaR 1.0 assay for molecular residual disease detection at the 2025 San Antonio Breast Cancer Symposium.